Preliminary Findings of a Phase Ib/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide (M+Len) in Previously Untreated (1L) Follicular Lymphoma (FL) - Archive ouverte HAL Accéder directement au contenu
Communication Dans Un Congrès Année : 2023

Preliminary Findings of a Phase Ib/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide (M+Len) in Previously Untreated (1L) Follicular Lymphoma (FL)

Franck Morschhauser
Krish Patel
Raul Cordoba
  • Fonction : Auteur
Toby A Eyre
Mark Bishton
Hui-Lai Zhang
  • Fonction : Auteur
Liqun Zou
Wendy Osborne
  • Fonction : Auteur
Laura Gálvez-Carvajal
Catherine Thieblemont
Donald Yee
  • Fonction : Auteur
Andrea Knapp
  • Fonction : Auteur
Enkhtsetseg Purev
  • Fonction : Auteur
Haocheng Li
Vivian Chen
Karl L. Banta
  • Fonction : Auteur
Jason Sit
  • Fonction : Auteur
Emmanuel Bachy

Dates et versions

hal-04344767 , version 1 (14-12-2023)

Identifiants

Citer

Franck Morschhauser, Krish Patel, Sabela Bobillo, Raul Cordoba, Toby A Eyre, et al.. Preliminary Findings of a Phase Ib/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide (M+Len) in Previously Untreated (1L) Follicular Lymphoma (FL). 65th ASH Annual Meeting, Dec 2023, San Diego, United States. pp.605, ⟨10.1182/blood-2023-174432⟩. ⟨hal-04344767⟩
6 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More